vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and GIBRALTAR INDUSTRIES, INC. (ROCK). Click either name above to swap in a different company.

GIBRALTAR INDUSTRIES, INC. is the larger business by last-quarter revenue ($225.0M vs $154.2M, roughly 1.5× BridgeBio Pharma, Inc.). On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 24.9%). GIBRALTAR INDUSTRIES, INC. produced more free cash flow last quarter ($26.2M vs $-56.5M).

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

Gibraltar Industries, Inc. is a leading manufacturer and distributor of specialized building, infrastructure, and renewable energy products. Its offerings include ventilation systems, roofing accessories, solar mounting solutions, and landscape and garden products, serving residential, commercial construction, and clean energy markets primarily across North America, with a focus on innovative, sustainable solutions for its customers.

BBIO vs ROCK — Head-to-Head

Bigger by revenue
ROCK
ROCK
1.5× larger
ROCK
$225.0M
$154.2M
BBIO
Growing faster (revenue YoY)
BBIO
BBIO
+2496.2% gap
BBIO
2521.2%
24.9%
ROCK
More free cash flow
ROCK
ROCK
$82.7M more FCF
ROCK
$26.2M
$-56.5M
BBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BBIO
BBIO
ROCK
ROCK
Revenue
$154.2M
$225.0M
Net Profit
$-194.6M
Gross Margin
94.7%
25.3%
Operating Margin
-90.5%
7.9%
Net Margin
-126.2%
Revenue YoY
2521.2%
24.9%
Net Profit YoY
27.2%
EPS (diluted)
$-1.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
ROCK
ROCK
Q4 25
$154.2M
$225.0M
Q3 25
$120.7M
$310.9M
Q2 25
$110.6M
$309.5M
Q1 25
$116.6M
$290.0M
Q4 24
$180.1M
Q3 24
$277.1M
Q2 24
$273.6M
Q1 24
$211.1M
$292.5M
Net Profit
BBIO
BBIO
ROCK
ROCK
Q4 25
$-194.6M
Q3 25
$-184.9M
$-89.1M
Q2 25
$-183.8M
$26.0M
Q1 25
$-169.6M
$21.1M
Q4 24
Q3 24
$34.0M
Q2 24
$32.2M
Q1 24
$-36.2M
$24.9M
Gross Margin
BBIO
BBIO
ROCK
ROCK
Q4 25
94.7%
25.3%
Q3 25
94.6%
26.6%
Q2 25
96.7%
28.4%
Q1 25
97.7%
26.8%
Q4 24
29.0%
Q3 24
29.4%
Q2 24
30.5%
Q1 24
99.7%
28.9%
Operating Margin
BBIO
BBIO
ROCK
ROCK
Q4 25
-90.5%
7.9%
Q3 25
-120.3%
12.8%
Q2 25
-121.4%
12.8%
Q1 25
-89.5%
8.8%
Q4 24
13.3%
Q3 24
15.6%
Q2 24
14.9%
Q1 24
0.2%
10.8%
Net Margin
BBIO
BBIO
ROCK
ROCK
Q4 25
-126.2%
Q3 25
-153.2%
-28.6%
Q2 25
-166.2%
8.4%
Q1 25
-145.4%
7.3%
Q4 24
Q3 24
12.3%
Q2 24
11.8%
Q1 24
-17.1%
8.5%
EPS (diluted)
BBIO
BBIO
ROCK
ROCK
Q4 25
$-1.00
Q3 25
$-0.95
$-2.98
Q2 25
$-0.95
$0.87
Q1 25
$-0.88
Q4 24
Q3 24
$1.11
Q2 24
$1.05
Q1 24
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
ROCK
ROCK
Cash + ST InvestmentsLiquidity on hand
$570.1M
$115.7M
Total DebtLower is stronger
$2.0B
$0
Stockholders' EquityBook value
$-2.1B
$950.4M
Total Assets
$936.0M
$1.4B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
ROCK
ROCK
Q4 25
$570.1M
$115.7M
Q3 25
$643.0M
$89.4M
Q2 25
$756.9M
$43.3M
Q1 25
$540.6M
$25.1M
Q4 24
$269.5M
Q3 24
$228.9M
Q2 24
$179.1M
Q1 24
$519.7M
$146.7M
Total Debt
BBIO
BBIO
ROCK
ROCK
Q4 25
$2.0B
$0
Q3 25
$2.0B
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$0
Stockholders' Equity
BBIO
BBIO
ROCK
ROCK
Q4 25
$-2.1B
$950.4M
Q3 25
$-1.9B
$951.8M
Q2 25
$-1.8B
$1.0B
Q1 25
$-1.6B
$1.0B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$975.7M
Q1 24
$-1.0B
$940.2M
Total Assets
BBIO
BBIO
ROCK
ROCK
Q4 25
$936.0M
$1.4B
Q3 25
$998.3M
$1.4B
Q2 25
$1.1B
$1.5B
Q1 25
$881.6M
$1.4B
Q4 24
$1.4B
Q3 24
$1.4B
Q2 24
$1.4B
Q1 24
$849.3M
$1.3B
Debt / Equity
BBIO
BBIO
ROCK
ROCK
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
ROCK
ROCK
Operating Cash FlowLast quarter
$-56.4M
$35.5M
Free Cash FlowOCF − Capex
$-56.5M
$26.2M
FCF MarginFCF / Revenue
-36.6%
11.7%
Capex IntensityCapex / Revenue
0.0%
4.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$120.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
ROCK
ROCK
Q4 25
$-56.4M
$35.5M
Q3 25
$-109.6M
$73.0M
Q2 25
$-80.7M
$44.9M
Q1 25
$-199.2M
$13.7M
Q4 24
$19.9M
Q3 24
$64.7M
Q2 24
$36.5M
Q1 24
$-219.5M
$53.2M
Free Cash Flow
BBIO
BBIO
ROCK
ROCK
Q4 25
$-56.5M
$26.2M
Q3 25
$-110.0M
$64.8M
Q2 25
$-81.3M
$27.3M
Q1 25
$2.3M
Q4 24
$14.1M
Q3 24
$60.5M
Q2 24
$33.5M
Q1 24
$-220.2M
$48.8M
FCF Margin
BBIO
BBIO
ROCK
ROCK
Q4 25
-36.6%
11.7%
Q3 25
-91.2%
20.8%
Q2 25
-73.5%
8.8%
Q1 25
0.8%
Q4 24
7.8%
Q3 24
21.8%
Q2 24
12.2%
Q1 24
-104.3%
16.7%
Capex Intensity
BBIO
BBIO
ROCK
ROCK
Q4 25
0.0%
4.1%
Q3 25
0.4%
2.6%
Q2 25
0.5%
5.7%
Q1 25
0.0%
3.9%
Q4 24
3.3%
Q3 24
1.5%
Q2 24
1.1%
Q1 24
0.3%
1.5%
Cash Conversion
BBIO
BBIO
ROCK
ROCK
Q4 25
Q3 25
Q2 25
1.73×
Q1 25
0.65×
Q4 24
Q3 24
1.90×
Q2 24
1.13×
Q1 24
2.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBIO
BBIO

Segment breakdown not available.

ROCK
ROCK

Transferred At Point In Time$183.5M82%
Infrastructure$22.5M10%
Other$18.9M8%

Related Comparisons